Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis

European Neuropsychopharmacology

Volumn 23, Issue 2, 2013, Pages 126-132

  Bloemen, Oswald J N ^a   de Koning, Mariken B ^a   Gleich, Tobias ^a   Meijer, Julia ^a   de Haan, Lieuwe ^a   Linszen, Don H ^a   Booij, Jan ^a   Van Amelsvoort, Thérèse A M J ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

AMPT; Depletion; Dopamine; Schizophrenia; SPECT; Striatum; UHR

Indexed keywords

6 FLUORODOPA F 18; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; IOLOPRIDE I 123; METIROSINE; NEUROLEPTIC AGENT; TRACER; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DRD2 PROTEIN, HUMAN; HOMOVANILLIC ACID; PROLACTIN; PYRROLIDINE DERIVATIVE; TYROSINE 3 MONOOXYGENASE; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; DIAGNOSTIC AGENT;

ARTICLE; BLOOD ANALYSIS; CLINICAL PROTOCOL; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINE METABOLISM; HIGH RISK PATIENT; HUMAN; NEUROTRANSMISSION; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URINALYSIS; ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; FEMALE; FUNCTIONAL NEUROIMAGING; MALE; METABOLISM; PROCEDURES; PSYCHOLOGY; PSYCHOTIC DISORDERS; RADIOASSAY; URINE; DRUG ANTAGONISM; DRUG EFFECT; METHODOLOGY; PSYCHOLOGICAL ASPECT;

ADULT; ALPHA-METHYLTYROSINE; BENZAMIDES; CASE-CONTROL STUDIES; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINERGIC NEURONS; FEMALE; FUNCTIONAL NEUROIMAGING; HOMOVANILLIC ACID; HUMANS; MALE; PROLACTIN; PSYCHOTIC DISORDERS; PYRROLIDINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TYROSINE 3-MONOOXYGENASE;

EID: 84873526852     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.04.015     Document Type: Article

References (39)

1. Abeling N.G., van Gennip A.H., Overmars H., Voute P.A. Simultaneous determination of catecholamines and metanephrines in urine by HPLC with fluorometric detection. Clin. Chim. Acta 1984, 137(2):211-226.
2. 2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. 2000, 97(14):8104-8109.
3. Abi-Dargham A., van de Giessen E., Slifstein M., Kegeles L.S., Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol. Psychiatry 2009, 65(12):1091-1093.
4. Bloemen O.J., de Koning M.B., Boot E., Booij J., van Amelsvoort T.A. Challenge and therapeutic studies using alpha-methyl-para-tyrosine (AMPT) in neuropsychiatric disorders: a review. Cent. Nerv. Syst. Agents Med. Chem. 2008, 8(4):249-256.
5. Bloemen O.J., Gleich T., Koning M.B., et al. Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. Biol. Psychiatry 2011.
6. Booij J., Korn P., Linszen D.H., Van Royen E.A. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur. J. Nucl. Med. 1997, 24(6):674-677.
7. Booij J., Tissingh G., Boer G.J., et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1997, 62(2):133-140.
8. Boot E., Booij J., Hasler G., et al. AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(7):1350-1356.
9. Cannon T.D., Cadenhead K., Cornblatt B., et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008, 65(1):28-37.
10. Fusar-Poli P., Howes O.D., Allen P., et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch. Gen. Psychiatry 2010, 67(7):683-691.
11. 3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 2009, 34(4):1078-1086.
12. de Haan L., Booij J., Lavalye J., van A.T., Linszen D. Subjective experiences during dopamine depletion. Am. J. Psychiatry 2005, 162(9):1755.
13. Hasler G., Fromm S., Carlson P.J., et al. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch. Gen. Psychiatry 2008, 65(5):521-531.
14. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Grasby P.M., McGuire P.K. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br. J. Psychiatry Suppl. 2007, 51:s13-s18.
15. Howes O.D., Montgomery A.J., Asselin M.C., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66(1):13-20.
16. Howes O.D., Bose S.K., Turkheimer F., et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am. J. Psychiatry 2011.
17. Howes O., Bose S., Turkheimer F., et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol. Psychiatry 2011.
18. Innis R.B., Cunningham V.J., Delforge J., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27(9):1533-1539.
19. Kaasinen V., Aalto S., Nagren K., Rinne J.O. Dopaminergic effects of caffeine in the human striatum and thalamus. Neuroreport 2004, 15(2):281-285.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
21. Kegeles L.S., Abi-Dargham A., Frankle W.G., et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch. Gen. Psychiatry 2010, 67(3):231-239.
22. de Koning M.B., Bloemen O.J., van Amelsvoort T.A., et al. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr. Scand. 2009, 119(6):426-442.
23. Klosterkotter J., Hellmich M., Steinmeyer E.M., Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry 2001, 58(2):158-164.
24. Laruelle M., Abi-Dargham A., van Dyck C.H., et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med. 1995, 36(7):1182-1190.
25. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997, 17(3):162-174.
26. Martinez D., Greene K., Broft A., et al. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am. J. Psychiatry 2009, 166(10):1170-1177.
27. McGorry P.D., Nelson B., Amminger G.P., et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J. Clin. Psychiatry 2009, 70(9):1206-1212.
28. Miller T.J., McGlashan T.H., Rosen J.L., et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003, 29(4):703-715.
29. 2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride. Biol. Psychiatry 2008, 63(2):241-244.
30. Ruhrmann S., Schultze-Lutter F., Salokangas R.K., et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch. Gen. Psychiatry 2010, 67(3):241-251.
31. Spitzer R.L., Williams J.B., Gibbon M, First M.B. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch. Gen. Psychiatry 1992, 49(8):624-629.
32. Stone J.M., Howes O.D., Egerton A., et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol. Psychiatry 2010, 68(7):599-602.
33. Stroomer A.E., Overmars H., Abeling N.G., van Gennip A.H. Simultaneous determination of acidic 3,4-dihydroxyphenylalanine metabolites and 5-hydroxyindole-3-acetic acid in urine by high-performance liquid chromatography. Clin. Chem. 1990, 36(10):1834-1837.
34. 2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 2001, 25(2):213-223.
35. Wechsler D. Wechsler Adult Intelligence Scale Revised 1987, Psychological Corporation, Harcourt Brace, New York, NY.
36. World Health Organization, 1993. Composite International Diagnostic Interview-Version 1.1. Geneva.
37. Yung A.R., Phillips L.J., Yuen H.P., et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 2003, 60(1):21-32.
38. Yung A.R., Phillips L.J., Yuen H.P., McGorry P.D. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004, 67(2-3):131-142.
39. Yung A.R., Nelson B., Stanford C., et al. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr. Res. 2008, 105(1-3):10-17.